Division of Surgical Oncology, Department of Surgery, Wake Forest University, Winston Salem, NC.
Department of Biostatistics and Data Science, Wake Forest University, Winston Salem, NC.
Ann Surg. 2021 Dec 1;274(6):1058-1066. doi: 10.1097/SLA.0000000000003770.
To identify the survival benefit of different adjuvant approaches and factors influencing their efficacy after upfront resection of pancreatic ductal adenocarcinoma (PDAC).
The optimal adjuvant approach for PDAC remains controversial.
Patients from the National Cancer Database who underwent upfront PDAC resection from 2010 to 2014 were analyzed to determine clinical outcomes of different adjuvant treatment approaches, stratified according to pathologic characteristics. Factors associated with overall survival were identified with multivariable logistic regression and Cox proportional hazards were used to compare overall survival of different treatment approaches in the whole cohort, and propensity score matched groups.
We included 16,709 patients who underwent upfront resection of PDAC. On multivariable analysis, tumor size, grade, positive margin, nodal involvement, lymphovascular invasion (LVI), stage, lymph node ratio, not receiving chemotherapy, and/or radiation were predictors for worse survival. In the presence of at least 1 high-risk pathologic feature (nodal or margin involvement or LVI) chemotherapy with subsequent radiation provided the most significant survival benefit (median survivals: 24.8 vs 21.0 mo for adjuvant chemotherapy; HR = 0.81; 95% CI: 0.77-0.86; P < 0.001 in propensity score matching). The addition of radiation to adjuvant chemotherapy did not significantly improve overall survival in those with no high-risk pathologic features (median survivals: 54.6 vs 42.7 mo for adjuvant chemotherapy; HR=0.90; 95% CI: 0.75-1.08; P = 0.25 in propensity score matching).
In the presence of any high-risk pathologic features (nodal or margin involvement or LVI), adjuvant chemotherapy followed by radiation provides a better survival advantage over chemotherapy alone after upfront resection of PDAC.
确定不同辅助治疗方法对胰腺导管腺癌(PDAC)患者根治性切除术后生存获益的影响,并识别影响疗效的因素。
PDAC 的最佳辅助治疗方法仍存在争议。
分析 2010 年至 2014 年期间在国家癌症数据库中接受 PDAC 根治性切除术的患者,根据病理特征对不同辅助治疗方法的临床结局进行分层分析。采用多变量逻辑回归确定与总生存期相关的因素,并使用 Cox 比例风险模型比较全队列和倾向评分匹配组中不同治疗方法的总生存期。
共纳入 16709 例接受 PDAC 根治性切除术的患者。多变量分析显示,肿瘤大小、分级、阳性切缘、淋巴结受累、脉管侵犯(LVI)、分期、淋巴结比值、未接受化疗和/或放疗是生存较差的预测因素。在存在至少 1 个高危病理特征(淋巴结或切缘受累或 LVI)的情况下,化疗联合后续放疗可获得最大的生存获益(辅助化疗的中位生存时间:24.8 个月比 21.0 个月;HR=0.81;95%CI:0.77-0.86;P<0.001,倾向评分匹配)。对于无高危病理特征的患者,化疗联合放疗并不能显著提高总生存期(辅助化疗的中位生存时间:54.6 个月比 42.7 个月;HR=0.90;95%CI:0.75-1.08;P=0.25,倾向评分匹配)。
对于存在任何高危病理特征(淋巴结或切缘受累或 LVI)的患者,PDAC 根治性切除术后,辅助化疗联合放疗比单纯化疗更能获得生存优势。